T-Cell Therapy Market Growth

According to a recently published report by Roots Analysis, the increased investment in research and development of cell therapies, along with growing interest of drug developers in personalized medicine, is driving the T-cell market growth

T-Cell Therapy Industry Overview

The global T-cell therapy market size to reach USD 20.9 billion by 2035, representing a CAGR of 12% in the forecast period. 

T-Cell therapies (which includes CAR-T, TIL and TCR therapies) are a class of biologic products that involves the use of either autologous or allogeneic whole cells that may or may not be modified, to invoke an immune response to fight a disease. Currently, close to 15 T-cell therapies are commercially available for the treatment of various disorders, including diffuse large B-cell lymphoma and multiple myeloma. Additionally, more than 1,040 candidates are currently being evaluated across various phases of clinical trials and around 345 cell therapies are being developed across preclinical and discovery stages of development. It is worth highlighting that these therapies have demonstrated tremendous potential in revolutionizing the cancer treatment, with promising results in achieving complete disease remission. As such, the demand for cell therapies is increasing substantially, thereby encouraging cell therapy companies and non-industry players to enhance their R&D capabilities in order to develop and advance a greater number of therapies towards the commercial market. Driven by the growing demand for targeted therapies, the T-cell therapy market size is poised to experience a noteworthy increase during the forecast period.

Browse 445+ figures and 490+ market data tables and detailed Table of Content on “T-Cell Therapy Market” by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Multiple Myeloma, Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Follicular Lymphoma and High grade B-cell lymphoma, Acute Lymphoblastic Leukemia / B-cell Non Hodgkin Lymphoma, Non Hodgkin Lymphoma, Mantle Cell Lymphoma, Acute Myeloid Leukemia, Generalized Myasthenia Gravis (MG), Renal transplantation (HLA-A2 -), Gastric Adenocarcinoma, Ovarian / Endometrial Cancer, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Renal Cell Carcinoma, Melanoma, Basal Cell Carcinoma, Lung Cancer, Sarcoma, Head And Neck Cancer, Cervical Cancer, Neuro Gastro-Intestinal (GI) Cancer, Breast Cancer, Hepatocellular Carcinoma, Nasopharyngeal Carcinoma and Ovarian Cancer), Target Antigens (BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and Others), Company Size (Small, Mid-sized and Large), Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World), Leading Players and Sales Forecast of Therapies: Industry Trends and Global Forecasts, till 2035” here: https://www.rootsanalysis.com/reports/t-cell-therapies-market/261.html

Market Drivers

Several factors are propelling the T-cell therapy market growth. One of the key factors driving the future of the global T-cell therapy market is the growing preference for personalized healthcare wherein treatments are tailored to engineer patient-specific T cells that precisely recognize and eliminate disease-causing cells. Additionally, the introduction of several expedited drug approval pathways (including orphan drug designation and accelerated approval processes) by regulatory bodies have encouraged the drug developers to focus on development of advanced cell therapies and facilitate their approval. 

Market Restraints

One of the primary restraints of this industry is the compliance to the stringent regulatory guidelines for cell therapies. In addition, these therapies are associated with exorbitant development costs as compared to conventional therapies primarily due to the fact that these therapies are highly personalized and require tailored development, as well as manufacturing processes. Moreover, challenges in scaling up manufacturing, establishing robust regulatory frameworks, and further documenting the extensive efficacy data obtained from clinical trials may limit the pace of market expansion. 

Growth Factors

Despite the challenges and various market restraints, several growth factors continue to drive the T-cell therapy market. The growing investments in cell therapies research and development by biotech firms, research institutions and pharmaceutical companies have been a key factor driving the growth of the T-cell therapy market. Additionally, the versatility and efficacy of T-cell therapy-based approaches, which enable the development of tailored treatments for a wide range of cancer disorders is further propelling the demand for T-cell therapies. Moreover, collaborations among pharmaceutical companies, academic institutions, and research organizations to address unmet medical needs globally, are likely to drive considerable growth in the market.

T-Cell Therapy Market Segments

Based on the type of therapy, the market is segmented into CAR-T therapy, TCR therapy and TIL therapy

• The CAR-T therapy segment is likely to capture the largest revenue share of close to 90% in the T-cell therapy market, in the current year.
• The TIL therapies segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 28.5%, during the forecast period.

Based on the target antigens, the market is segmented into BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and others

• The CD19 segment is likely to capture the largest revenue share of close to 55% in the T-cell therapy market, in the current year.
• The CD 19 and CD 22 segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 76.9%, during the forecast period.

Based on the company size, the market is segmented into small, mid-sized and large companies

• The mid-sized companies segment is likely to capture the largest revenue share of close to 70% in the T-cell therapy market, in the current year.
• The large companies segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 22.1%, during the forecast period.

Based on target indication, the market is segmented into multiple myeloma, large B-cell lymphoma, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma and high grade B-cell lymphoma, acute lymphoblastic leukemia / B-cell non hodgkin lymphoma, non hodgkin lymphoma, mantle cell lymphoma, acute myeloid leukemia, generalized myasthenia gravis (MG), renal transplantation (HLA-A2 -), gastric adenocarcinoma, ovarian / endometrial cancer, chronic lymphocytic leukemia, follicular lymphoma, renal cell carcinoma, melanoma, basal cell carcinoma, lung cancer, sarcoma, head and neck cancer, cervical cancer, neuro gastro-intestinal (GI) cancer, breast cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and ovarian cancer

• The multiple myeloma segment is likely to capture the largest revenue share of around 40% in the T-cell therapy market, in the current year.
• The diffuse large B-cell lymphoma segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 13.4%, during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World

• North America is expected to dominate the T-cell therapy market, accounting for the largest revenue share (close to 75%) in the current year.
• In Asia-Pacific, the T-cell therapy market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The T-Cell Therapy market report also includes profiles of key players (listed below) that are engaged in the T-Cell Therapy domain:

• Adaptimmune Therapeutics
• AbelZeta
• Alaunos Therapeutics
• Autolus Therapeutics
• bluebird bio
• Bristol Myers Squibb
• CARsgen Therapeutics
• Cellectis
• Gilead Sciences
• Immatics
• Immunocore
• Innovative Cellular Therapeutics
• Iovance Biotherapeutics
• Kuur Therapeutics
• Lion TCR
• Noile-Immune Biotech
• Novartis
• Takara Bio
• Wellington Zhaotai Therapies
• Zelluna immunotherapy 

You Can Download Free Sample PDF Copy of This Report At: 
https://www.rootsanalysis.com/reports/t-cell-therapies-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com